Pfizer Inc.
EZH2 INHIBITOR COMBINATION THERAPIES
Last updated:
Abstract:
This invention relates to combination therapies comprising an EZH2 inhibitor and a chemotherapeutic agent, and associated pharmaceutical compositions, methods of treatment, and pharmaceutical uses.
Status:
Application
Type:
Utility
Filling date:
9 Nov 2018
Issue date:
27 Aug 2020